Tai H and Zhang Z |
A novel compound heterozygous mutation in a Chinese boy with L-2-hydroxyglutaric aciduria: a case study. |
2015 |
BMC Neurol |
pmid:26208971
|
Fu X et al. |
2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. |
2015 |
Cell Metab. |
pmid:26190651
|
Hwang VJ et al. |
The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. |
2015 |
Am. J. Physiol. Renal Physiol. |
pmid:26155843
|
Macaulay RJ |
Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. |
2015 |
Cancer Control |
pmid:26068765
|
Suijker J et al. |
The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo. |
2015 |
Oncotarget |
pmid:26046462
|
Izquierdo-Garcia JL et al. |
IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. |
2015 |
Cancer Res. |
pmid:26045167
|
Pichumani K et al. |
Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas. |
2015 |
Anal. Biochem. |
pmid:25908561
|
Lombardi G et al. |
Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. |
2015 |
Oncologist |
pmid:25862748
|
Natsumeda M et al. |
Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. |
2014 |
Acta Neuropathol Commun |
pmid:25376594
|
Chittaranjan S et al. |
Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. |
2014 |
Oncotarget |
pmid:25277207
|
Liu Z et al. |
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. |
2014 |
J. Med. Chem. |
pmid:25271760
|
Shim EH et al. |
L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. |
2014 |
Cancer Discov |
pmid:25182153
|
Saha SK et al. |
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. |
2014 |
Nature |
pmid:25043045
|
Pope WB |
Intraoperative mass spectrometry of tumor metabolites. |
2014 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:25028494
|
Reitman ZJ et al. |
Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. |
2014 |
J. Biol. Chem. |
pmid:24986863
|
Santagata S et al. |
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. |
2014 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:24982150
|
Kato Kaneko M et al. |
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. |
2014 |
Cancer Sci. |
pmid:24898068
|
Fathi AT et al. |
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. |
2014 |
Oncologist |
pmid:24760710
|
Elhammali A et al. |
A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. |
2014 |
Cancer Discov |
pmid:24740997
|
Gilbert MR et al. |
Autophagy and oxidative stress in gliomas with IDH1 mutations. |
2014 |
Acta Neuropathol. |
pmid:24150401
|